Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study.
Astrid LipplaaWillem H SchreuderSarina E C PichardoAndré B P van KuilenburgPublished in: The oncologist (2023)
Due to critical emerging real-world data of denosumab in GCRTBs, the study was prematurely stopped and not supportive of use of denosumab for this indication. (ClinicalTrials.gov Identifier: NCT03605199).